Biosimilar Newsletter Archive
-
12.10.20 -- Why Severability Should Be In Your Biosimilar Vocabulary
12/10/2020
12/10/20 Biosimilar Development Newsletter
-
12.08.20 -- New Podcast Episodes: 2021 Trends For Biotech, Modulation Of The Microbiome And Biopharma Financing
12/8/2020
12/08/20 Biosimilar Development Newsletter
-
12.03.20 -- 3 Perspectives On Biosimilars & Biobetter Development
12/3/2020
12/03/20 Biosimilar Development Newsletter
-
11.25.20 -- Biosimilar Or Biobetter? Perspectives On An Evolving Market
11/25/2020
11/25/20 Biosimilar Development Newsletter
-
11.20.20 -- It's Never Too Early To Think About Automation
11/20/2020
11/20/20 Biosimilar Development Newsletter
-
11.19.20 -- IQVIA's U.S. Biosimilar Report: Your Most Pressing Questions Answered
11/19/2020
11/19/20 Biosimilar Development Newsletter
-
11.12.20 -- The Little-Known Drivers Behind 2020's Biosimilar Boom
11/12/2020
11/12/20 Biosimilar Development Newsletter
-
11.10.20 -- How To Predict And Prepare For Illusive Cell Therapy Issues
11/10/2020
11/10/20 Biosimilar Development Newsletter
-
11.06.20 -- Strategies To Accelerate Process Development
11/6/2020
11/06/20 Biosimilar Development Newsletter
-
11.05.20 -- Biosimilar Manufacturing: The Past, Present, & Future
11/5/2020
11/05/20 Biosimilar Development Newsletter
This website uses cookies to ensure you get the best experience on our website. Learn more